Department of Genetics, Federal University of Parana, Curitiba, Brazil.
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Genet. 2019 May;95(5):558-568. doi: 10.1111/cge.13502. Epub 2019 Jan 22.
Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non-coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.
乳腺癌(BC)是最常见的癌症,也是女性癌症死亡的主要原因。BC 是一种具有不同临床和遗传特征的异质性疾病。根据免疫组织化学标志物,BC 可分为四个主要亚型:腔 A 型、腔 B 型、ERBB2 阳性和三阴性。长链非编码 RNA(lncRNA)是长度超过 200 个核苷酸的转录物,失调的 lncRNA 与人类疾病有关,包括 BC。为了提高 BC 的分子分类,包括 lncRNA 在内的非编码 RNA(ncRNA)已被用于该研究。在这篇综述中,我们重点介绍了在 BC 亚型中差异表达的 lncRNAs 以及这些 RNA 如何作用以促进 BC 的异质性。我们还强调了这些 lncRNAs 作为生物标志物的潜力。